Operator: Good afternoon, ladies and gentlemen, and welcome to the Cue Biopharma Third Quarter 2023 Earnings Call. At this time, all lines are in listen-only mode.
Overall response rate of 47% and disease control rate of 65% in first line recurrent/metastatic HNSCC patients treated with CUE-101 and KEYTRUDA® ORR of 56% in patients with low expression of.
Operator: Greetings, and welcome to the Cue Biopharma Investor Update Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the presentation.
BOSTON, May 09, 2023 Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T. | May 9, 2023